- The co-primary endpoint of safety will be determined by rate, severity, and duration of adverse events based on CTCAE v4 criteria. Assessment for DLTs will occur every 2 weeks during the first 4 weeks of each dose level. Safety monitoring will occur every 4 weeks thereafter.